At a glance

IGF-1 LR3 Quick Reference

Community range: 40–80mcg daily
SubQ or IM reports; not validated
Cycle: 4–6 weeks
Community convention
Primary target: IGF-1 receptor
Reduced IGF-binding-protein affinity
Major risk: Low blood glucose
Especially with insulin or glucose-lowering drugs

Overview

What Is IGF-1 LR3?

IGF-1 LR3 means Long Arg3 Insulin-Like Growth Factor 1. It is an 83-amino-acid analog of the 70-amino-acid native IGF-1 molecule. An arginine substitution at position 3 and a 13-amino-acid N-terminal extension reduce its affinity for IGF-binding proteins.

Binding proteins regulate how native IGF-1 circulates and reaches receptors. LR3’s weaker binding can leave more analog available to act at the IGF-1 receptor in experimental systems. Cell and animal studies report stronger activity in some settings; the often-repeated human half-life and potency numbers have not been established in a human LR3 pharmacokinetic trial.

Recombinant native IGF-1 is an approved medicine for a narrow pediatric indication, but that approval does not apply to LR3. IGF-1 LR3 has no established human therapeutic dose, long-term safety profile, or approved indication. It is also prohibited in tested sport under growth-factor rules.

Mechanism

IGF-1 LR3 Mechanism of Action

Altered IGF-1 structure

The Arg3 substitution and N-terminal extension distinguish LR3 from native IGF-1.

Reduced IGFBP binding

LR3 binds IGF-binding proteins much less strongly, changing receptor availability in experimental systems.

IGF-1 receptor signaling

IGF-1 receptor activation affects growth, survival, glucose uptake, and tissue remodeling pathways.

Systemic exposure

The same signaling creates concern about hypoglycemia, edema, and unwanted growth; human LR3 outcomes are unknown.

Research findings

IGF-1 LR3 Benefits

Most claims extrapolate from native IGF-1 biology or cell and animal LR3 experiments; controlled human LR3 benefit has not been established.

Muscle Growth Models

IGF-1 receptor signaling supports myoblast proliferation and protein synthesis in experimental systems, but LR3 has no proven human hypertrophy outcome.

Satellite-Cell Research

Laboratory studies explore muscle precursor activation and repair signaling after IGF exposure.

Recovery & Repair

Animal and cell research suggests tissue-repair roles for IGF signaling; claims of faster human recovery with LR3 remain anecdotal.

Glucose Uptake

IGF signaling can increase glucose uptake. This is a pharmacologic effect and a source of acute hypoglycemia risk, not an uncomplicated benefit.

Bone & Connective Tissue

Native IGF-1 participates in skeletal and connective-tissue growth, but LR3 treatment has not been validated for these uses in people.

Body Composition Reports

Community reports describe fuller muscles or changes in training response, but diet, other hormones, and training make attribution difficult.

Protocol planning

IGF-1 LR3 Dosing Protocol

SubQ and IM injection appear in community protocols. The ranges below are anecdotal and neither route has a human LR3 dose-finding or safety study. Glucose-lowering effects are a central risk.

Members Access Only

Sign in or create a free account to view this content.

Preparation

IGF-1 LR3 Reconstitution

Example concentration

1mg vial + 1mL compatible 0.6% acetic acid solution

Result1mg/mL

Reconstitution steps

1

Prepare

Wash hands, clean the surface, and wipe vial stoppers with alcohol. Let them dry.

2

Add compatible diluent slowly

For this example, direct 1mL of supplier-confirmed 0.6% acetic acid solution down the vial wall.

3

Dissolve gently

Allow the powder to dissolve; roll or swirl gently if needed. Do not shake.

4

Store

Store refrigerated and away from light according to product-specific instructions. Record the reconstitution date in your research journal.

N=1 reports

IGF-1 LR3 Community Experience

Positive Reports

Some users describe increased muscle fullness or recovery during training blocks.
Others report stronger appetite or changes in workout response.

Negative & Mixed Reports

Low-glucose symptoms, including shakiness or weakness, are a major concern.
Edema, numbness, joint discomfort, headache, and injection-site irritation appear in reports.
Concurrent anabolic agents and training changes make benefits difficult to attribute.

Stacking & synergy

IGF-1 LR3 Stacking & Synergy

IGF-1 receptor effects can make combinations unpredictable. None of these pairings has a controlled human LR3 safety study.

LR3 + GH Secretagogues

IGF-1 negative feedback may alter GH pulses. The timing and net effect of this community combination are untested.

LR3 + TRT

Different anabolic pathways are involved, but combined edema, blood-pressure, cardiac, metabolic, or proliferative risks are unresolved.

LR3 + GLP-1 Agonists

Reduced food intake could complicate low-glucose symptoms during IGF signaling; no established interaction trial exists.

LR3 + Insulin

A particularly dangerous pairing because both can lower glucose. Severe hypoglycemia is possible and requires specialist oversight.

Safety notes

IGF-1 LR3 Side Effects & Safety

No approved human LR3 program defines its adverse-effect rate. Risk assessment draws on IGF biology, native IGF-1 medicines, animal studies, and community reports.

Acute Concerns

Hypoglycemia or low-glucose symptoms such as sweating, tremor, confusion, fainting, or seizure.
Water retention, edema, bloating, joint discomfort, headache, or fatigue.
Injection-site reactions or numbness and tingling.

Longer-Term Concerns

Sustained growth signaling may affect organs, cardiovascular tissue, and glucose regulation.
Potential stimulation of abnormal or malignant cells remains a concern.
Human LR3 immunogenicity, pharmacokinetics, and repeated-use outcomes are unknown.

IGF-1 LR3 Precautions

Avoid or Discuss With a Clinician If

Active or prior cancer without oncology approval.
Diabetes or use of insulin or glucose-lowering medication without specialist supervision.
Proliferative retinal disease, pregnancy, breastfeeding, or known hypersensitivity.

Use Extreme Caution With

History of hypoglycemia, cardiovascular disease, edema, or abnormal growth regulation.
Concurrent GH, secretagogues, anabolic agents, or GLP-1 therapy.
An unverified product, formulation, or preparation method.

IGF-1 LR3 is not FDA approved for human use and is prohibited in tested sport under growth-factor rules.

Final verdict

Peptide Protocols Verdict on IGF-1 LR3

Our opinionated opinion

IGF-1 LR3 has obvious anabolic appeal on paper. The reduced binding-protein affinity makes it more than a cosmetic variation on native IGF-1, and we understand why advanced researchers pay attention to it.

For us, the risk-reward does not line up. Misjudging its glucose effects can be dangerous, and the uncertainty around sustained growth signaling is not a small tradeoff. We have seen enough concerning feedback that we will not use IGF-1 LR3 in-house. There are more predictable ways to pursue growth and recovery, so it stays at C and outside our recommended rotation.